SCHEMBL24110951

SCHEMBL24110951

O=c1c2ccccc2nc(Nc2ccn3nccc3c2)n1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.44
MAPT P10636 3/20 0.44
RIPK1 Q13546 1/20 0.41
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 3/20 0.41
POLB P06746 3/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
GAA P10253 1/20 0.40
LMNA P02545 1/20 0.40
NPY1R P25929 1/20 0.40
NPY2R P49146 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HSP90AA1 P07900 1/20 0.39
PDE7A Q13946 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24110801 0.79 USP2 (0.43) USP2MAPTALDH1A1KDM4EPOLB
SCHEMBL24090012 0.77 TOP2A (0.60) USP2MAPTALDH1A1POLBRAB9A
SCHEMBL24110995 0.75 ALOX12 (0.57) USP2MAPTRAB9AMEN1KMT2A
SCHEMBL24111024 0.74 USP2 (0.43) USP2MAPTALDH1A1KDM4EPOLB
SCHEMBL30103271 0.74 PRKD1 (0.49) USP2MAPTALDH1A1KDM4EPOLB
SCHEMBL23931384 0.74 PRKD1 (0.49) USP2MAPTALDH1A1KDM4EPOLB
SCHEMBL24110866 0.74 USP2 (0.43) USP2MAPTALDH1A1KDM4EPOLB
SCHEMBL23958135 0.74 PRKD1 (0.49) USP2MAPTALDH1A1KDM4EPOLB
SCHEMBL24089946 0.73 ACP1 (0.49) USP2MAPTALDH1A1RAB9ANPC1
SCHEMBL24111028 0.73 MAPT (0.45) USP2MAPTALDH1A1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210387967-A1 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210387967-A1 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE CRKL, CLIC4, CLIC1 USP2 3746/4885MAPT 4749/4885RIPK1 3060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.